These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2625847)

  • 1. [Diagnostic value of radioimmunological analysis of CA-19-9 in the blood serum in cancer of the pancreas].
    Putseva NM; Chebotareva ED; Chernyĭ VA; Tashchiev RK
    Klin Khir (1962); 1989; (11):15-7. PubMed ID: 2625847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The diagnostic value of determining the level of the carbohydrate antigen 19-9 in pancreatic cancer].
    Moroz GS; Les'kiv IM
    Klin Khir (1962); 1993; (2):34-5. PubMed ID: 10912065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
    Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
    Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
    Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood CA 19-9 in the diagnosis of carcinoma of the pancreas: a critical approach].
    Angonese C; Basso D; Del Favero G; Fabris C; Tremolada C; Plebani M; Burlina A; Naccarato R
    Ann Ital Med Int; 1987; 2(2):138-42. PubMed ID: 3275279
    [No Abstract]   [Full Text] [Related]  

  • 12. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic information value of determining tumor-associated antigen Ca-19-9 in pancreatic cancer].
    Samoĭlenko VM; Afrikian MN; Itin AB
    Vopr Onkol; 1989; 35(9):1050-3. PubMed ID: 2815692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
    Pei DP
    Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F; Roscher R; Beger HG
    Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy.
    DelMaschio A; Vanzulli A; Sironi S; Castrucci M; Mellone R; Staudacher C; Carlucci M; Zerbi A; Parolini D; Faravelli A
    Radiology; 1991 Jan; 178(1):95-9. PubMed ID: 1984331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.